Polydatin is an active
polyphenol displaying multifaceted benefits. Recently, growing studies have noticed its potential
therapeutic effects on bone and joint disorders (BJDs). Therefore, this article reviews recent in vivo and in vitro progress on the protective role of
polydatin against BJDs. An insight into the underlying mechanisms is also presented. It was found that
polydatin could promote osteogenesis in vitro, and symptom improvements have been disclosed with animal models of
osteoporosis,
osteosarcoma,
osteoarthritis and
rheumatic arthritis. These beneficial effects obtained in laboratory could be mainly attributed to the bone metabolism-regulating, anti-inflammatory, antioxidative, apoptosis-regulating and autophagy-regulating functions of
polydatin. However, studies on human subjects with BJDs that can lead to early identification of the clinical efficacy and adverse effects of
polydatin have not been reported yet. Accordingly, this review serves as a starting point for pursuing clinical trials. Additionally, future emphasis should also be devoted to the low bioavailability and prompt metabolism nature of
polydatin. In summary, well-designed clinical trials of
polydatin in patients with BJD are in demand, and its pharmacokinetic nature must be taken into account.